Table 4.
Health and economic outcomes – Lifetime incidence of disease per 100,000 women, costs, QALE, and ICER compared to next most effective strategy*
| Strategy | Cervical cancer cases | Cervical cancer deaths | Annual incidence of cervical cancer | Costs ($) | QALE (years) | ICER ($/QALY) |
|---|---|---|---|---|---|---|
| No screening | 1,383 | 894 | 20.64 | $86,700 | 28.5866 | -- |
| LBC only (2 year interval) | 615 | 259 | 9.17 | $88,162 | 28.6623 | $19,321 |
| LBC with HPV triage (2 year interval) | 574 | 231 | 8.56 | $88,221 | 28.6651 | $21,304 |
| HPV with LBC triage (3 year interval) | 527 | 193 | 7.86 | $88,226 | 28.6670 | $2,618 |
| HPV and LBC co-screening (3 year interval) | 502 | 184 | 7.49 | $88,303 | 28.6714 | $17,204 |
| HPV genotyping for HR HPV-positive women (3 year interval) | 507 | 180 | 7.57 | $88,340 | 28.6725 | $34,074 |
| HPV genotyping with co-screening (3 year interval) | 444 | 158 | 6.62 | $88,407 | 28.6745 | $33,807 |
*
ICER denotes incremental cost-effectiveness ratio, QALE quality-adjusted life expectancy, QALY quality-adjusted life year, LBC liquid-based cytology, HPV human papillomavirus, and HR high-risk.